This program is intended for endocrinologists and scientists who are involved and/or related to research on new insulin development and the care of patients with diabetes
The goal of this program is to improve the knowledge and competence of endocrinologists and scientists with the latest evidence on the mechanisms, efficacy, and safety of weekly insulin formulations in development and the potential for these treatments to address challenges with current insulin therapy and achievement of glycemic goals in patients with diabetes.
Upon completion of this activity, participants should be able to:
Identify challenges with daily basal insulin that may be overcome by weekly insulin formulations in development
Compare the mechanism of action, efficacy, and safety of weekly insulin formulations in development with available daily basal insulins
Evaluate strategies to address patient and provider barriers to implementing weekly insulins into clinical practice
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Rodolfo J. Galindo, MD, FACE
Associate Professor of Medicine
Division of Endocrinology
University of Miami Miller School of Medicine
Comprehensive Diabetes Center
UM Health System
Rodolfo J. Galindo, MD, FACE: researcher (paid to institution): Dexcom, Lilly, Novo Nordisk; consultant/advisor/speaker: Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk, Pfizer, Sanofi.
Juan Pablo Frias, MD, FACE
Medical Director and Principal Investigator
National Research Institute
Los Angeles, California
Juan Pablo Frias, MD: researcher (paid to institution): 89bio, Akero, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept, IONIS, Janssen, Lilly, Madrigal, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, Sanofi; consultant/advisor/speaker: 89bio, Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Gilead, Intercept, Lilly, Merck, Metacrine, Novo Nordisk, Pfizer, Sanofi.
Carol Hatch Wysham, MD
Clinical Professor of Medicine
Carol Hatch Wysham, MD: researcher (paid to institution): Corcept, Lilly, Novo Nordisk, Regeneron, Vanda.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Amy Butts, PA-C as noted below:
Amy Butts, PA-C: consultant/advisor/speaker: Abbott, Bayer, Novo Nordisk, Sanofi.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
AMA PRA Category 1 Credit
The Endocrine Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.
Physician Associate/Physician Assistant Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 31, 2024. PAs should only claim credit commensurate with the extent of their participation.